Alteration of serum markers in COVID-19 and implications on mortality

Dear editor,

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a global pandemic since its initial outbreak in Wuhan, China. Among the many unanswered questions for COVID-19, how to reduce mortality and improve survival of patients is the most critical. Evidence indicates that increased cytokine levels (also known as cytokine storm) might be a major contributor of disease deterioration in COVID-19 leading to death. Previous reports focused on cytokine storm in COVID-19 have been limited by shorter follow ups, small sample sizes, and evaluation of subgroups of patients. Longitudinal profile of cytokine variations in large cohort has not been comprehensively evaluated.

Here, we present an analysis of laboratory indices and cytokines, along with risk factors and mortality in patients with COVID-19 using a closed, multicenter retrospective cohort study. Overall, 2044 COVID-19 patients, who hospitalized in the Optical Valley Campus and Sino-French New City Campus of Tongji Hospital in Wuhan, China, between January 27 and March 21 and had definite outcome (discharge or death), were included in our analysis (Figure S1).

Overall, 235 patients died during hospitalization, while 1809 patients were discharged from the hospital (Table S1). The median (IQR) age of all patients was 62.0 (IQR 51.0-70.0) years, and 48.92% were men. Over half of the patients (1175, 57.63%) had at least one comorbidity. Patients who died were significantly older (median (IQR) age, 70 [63-78] vs 61 [49-69], \(P < .0001\)) and were more likely to be male (156 [66.38%] vs 844 [46.66%], \(P < .001\)) and to have comorbidities (189 [81.12%] vs 986 [54.60%], \(P < .001\)).

Cytokine profiles of patients are shown in Table S2. Over half of COVID-19 patients (1110, 57.33%) had increased C reactive protein (CRP) on admission. Elevated ferritin and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) occurred in 651 (56.17%) and 762 (46.15%) patients, respectively. Elevation of cytokines such as IL-2R and IL-6 occurred in 589 (35.61%) and 547 (32.89%) patients, respectively. Patients who died had significantly higher median levels of CRP (103.2 [61.2-169.1] vs 11.4 [2.0-51.1], \(P < .0001\)) and ferritin (1427.6 [848.2-2395.4] vs 494.4 [288.0-840.8], \(P < .0001\)) compared to the population who recovered. They also had significantly higher proportion of increased TNF-\(\alpha\) (75.54% vs 42.47%, \(P < .001\)) and multiple cytokines compared to survivors, such as IL-2R (1174.0 [828.5-1611.0] vs 529.0 [344.0-771.0], \(P < .0001\)) and IL-6 (62.67 [30.17-157.2] vs 4.31 [1.78-15.06], \(P < .0001\)). The details of treatments and outcomes are described in Table S3.

To depict the dynamic course of COVID-19 and further explore the risk factors associated with poor prognosis, cytokines and other significant indices were tracked over 6 weeks (shown in Figures S2 and S3). The mortality reached its peak approximately around the third week of illness from the onset. Similarly, elevations of D-dimer and cTnI were also observed around 3 weeks from the illness onset among patients with higher mortality. Lastly, in week 5-6, elevated levels of cytokines (including IL-2R, IL-6, IL-8, and IL-10, Ferritin, and TNF-\(\alpha\)) were seen among non-survivors compared with patients who recovered. Other laboratory indices, such as LDH, procalcitonin (PCT), and NT-proBNP, also peaked in the corresponding period.

To further understand the role of cytokine storm and other risk factors in COVID-19-related mortality, univariable logistic regression was performed as summarized in Table 1. Older patients were associated with increased odds of death than the younger. The risk of death increased proportionately with the number of comorbidities. The presence of severe respiratory symptoms and unstable vital signs on admission also predicted poor outcomes.

Surprisingly, we found that some risk factors of mortality disproportionately affected males compared to females. Hypertension (OR 2.88, 95% CI 2.02 to 4.11, \(P < .001\)) and coronary heart disease (CHD) (2.96, 1.88 to 4.67, \(P < .001\)) increased the odds of death in males but had no...
| Risk Factors with Differences between Males and Females | Univariable Analysis | Effect modification | Multivariable Analysis |
|--------------------------------------------------------|----------------------|---------------------|-----------------------|
|                                                        | Male | Female | Male | Female |
| Hypertension                                           | 2.88 (2.02-4.11)     | 1.07 (0.67-1.71)    | .779                  | <.001    | 2.04 (1.17-3.54) | .012   |
| CHD                                                    | 2.96 (1.88-4.67)     | 1.50 (0.74-3.02)    | .257                  | .044     |
| Tumor                                                  | 2.87 (1.36-6.04)     | 4.82 (2.07-11.22)   | <.001                 | .076     |
| CO PD                                                  | 3.50 (1.13-10.84)    | 18.99 (3.12-115.37) | .001                  | .064     |
| Platelet count, 10⁹/L <100 versus ≥100                | 7.58 (4.37-13.13)    | 13.93 (7.00-27.70)   | <.001                 | .082     |
| PT, s ≥17 versus <17                                   | 20.02 (10.34-38.78)  | 49.61 (19.11-128.82)| <.001                 | .094     |
| NT-proBNP, pg/mL >241 versus ≤241                     | 9.79 (6.49-14.77)    | 26.80 (14.34-50.09)  | <.001                 | .006     |
| C reactive protein, mg/L                              | 1.02 (1.01-1.02)     | 1.02 (1.02-1.03)    | <.001                 | .018     |
| Procalcitonin, ng/mL                                  | 10.73 (5.68-20.29)   | 11.88 (5.71-24.72)  | <.001                 | .058     |
| IL-2R, U/mL >710 versus ≤710                          | 6.08 (3.82-9.69)     | 14.56 (7.58-27.95)  | <.001                 | .041     |
| IL-6, pg/mL ≥62 versus <62                            | 1.02 (1.02-1.03)     | 1.04 (1.03-1.05)    | <.001                 | .005     |
| IL-8, pg/mL ≥62 versus <62                            | 6.47 (3.77-11.11)    | 11.88 (6.15-22.96)  | <.001                 | .060     |
| IL-10, pg/mL ≥8.1 versus <8.1                         | 1.03 (1.01-1.05)     | 1.22 (1.16-1.29)    | <.001                 | <.001    |
| TNFα, pg/mL ≥8.1 versus <8.1                          | 2.75 (1.78-4.27)     | 6.23 (3.42-11.35)   | <.001                 | .020     |
| Characteristics                                        |                    |                     |                       |
| Age, years                                             | 1.07 (1.05-1.08)     | 1.07 (1.05-1.09)    | <.001                 | <.001    |
| ≥50 years                                              | 20.03 (6.33-63.41)   | 7.49 (2.34-23.98)   | <.001                 | 5.90 (1.33-26.11) | .019   |
| Presence of comorbidities                              | 4.46 (2.82-7.03)     | 2.48 (1.47-4.18)    | <.001                 | <.001    |
| Number of comorbidities                                | 1.86 (1.58-2.19)     | 1.53 (1.24-1.88)    | <.001                 | <.001    |
| Respiratory rate, per min ≥24 versus <24              | 8.75 (5.97-12.82)    | 11.97 (7.03-20.39)  | <.001                 | <.001    |
| SpO2, % ≥93 versus >93                                 | 13.37 (8.71-20.54)   | 17.83 (10.06-31.62) | <.001                 | <.001    |
| SOFA                                                   | 4.24 (3.40-5.27)     | 3.61 (2.88-4.53)    | <.001                 | <.001    |

(Continues)
| Laboratory findings | Univariable Analysis Male (95% CI) | P-value | Male (95% CI) | P-value | Female (95% CI) | P-value | Female (95% CI) | P-value | Effect modification P-value | Male (95% CI) | P-value | Female (95% CI) | P-value |
|---------------------|-----------------------------------|---------|----------------|---------|-----------------|---------|-----------------|---------|-------------------|----------------|---------|-----------------|---------|
| WBC count, 10^9/L   | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| >10 versus ≤10      | 11.96 (7.77-18.43)                | <.001   | 24.35 (14.12-42.00) | <.001   | 5.64 (2.83-11.24) | <.001   | 6.87 (2.68-17.63) | <.001 |
| Lymphocyte count, 10^9/L <0.8 versus ≥0.8 | 8.21 (5.56-12.12) | <.001 | 10.49 (6.32-17.42) | <.001 | 3.47 (1.96-6.12) | <.001 | 3.65 (1.60-8.29) | .002 |
| Hemoglobin, g/L     | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| <120 versus ≥120    | 1.54 (1.01-2.34)                  | .043    | 1.91 (1.17-3.14) | .010    |                 |         |                 |         |
| BUN, mmol/L         | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| ≥10 versus <10      | 15.25 (9.56-24.30)                | <.001   | 27.34 (14.31-52.21) | <.001   |                 |         |                 |         |
| Creatinine, μmol/L  | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| ≥110 versus <110    | 4.42 (2.90-6.72)                  | <.001   | 10.31 (5.29-20.10) | <.001   |                 |         |                 |         |
| APTT, s             | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| ≥52 versus <52      | 5.99 (3.22-11.12)                 | <.001   | 3.82 (1.59-9.20) | .003    |                 |         |                 |         |
| D-dimer, μg/mL      | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| >1 versus ≤1        | 9.02 (5.65-14.39)                 | <.001   | 17.94 (8.51-37.79) | <.001   | 2.91 (1.56-5.44) | .001   |                 |         |
| High-sensitivity cardiac troponin I, pg/mL | 39.06 (23.10-66.05) | <.001 | 22.44 (13.02-38.68) | <.001 | 6.70 (3.02-14.89) | <.001 |
| Procalcitonin, ng/mL | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| ≥0.25 versus <0.25  | 11.53 (7.67-17.32)                | <.001   | 19.21 (10.86-34.00) | <.001   | 2.42 (1.33-4.41) | .004   |                 |         |
| C reactive protein, mg/L | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| >10 versus ≤10      | 22.90 (8.40-62.48)                | <.001   | 13.32 (5.72-31.06) | <.001   | 4.99 (0.98-25.31) |         |                 |         |
| Ferritin, μg/L      | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| Male >800 versus ≤800 | 5.08 (3.08-8.40)                  | <.001   | 18.01 (4.34-74.78) | <.001   |                 |         |                 |         |
| IL-6, pg/mL         | Male                              | Female  | Male           | Female  | Male            | Female | Male            | Female | Female            | Male            | Female | Male            | Female |
| ≥14 versus <14      | 16.63 (9.32-29.68)                | <.001   | 35.51 (15.04-83.86) | <.001   | 5.21 (2.65-10.27) | <.001   | 12.89 (4.71-35.30) | <.001 |

Abbreviations: CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease; HBV, hepatitis B virus; CKD, chronic kidney disease; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell; BUN, blood urea nitrogen; PT, prothrombin time; APTT, activated partial thromboplastin time; IL-2R, interleukin-2R; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; TNF-α, tumor necrosis factor-α.

1P < .05 was considered statistically significant.
2The statistical significance of effect modification between gender and other factors was tested using logistic regression models containing the interaction terms (gender and hypertension, gender, CHD, etc.).
3Upper limit of normal value (ULN) for males and females, separately.
4Two times of upper limit of normal value (ULN) for males and females, separately.
adverse influence on females (Figures S4 and S5). However, women with cancer and COPD had a higher risk of death compared to men. Females were also found to have increased odds of death in the cases of cytokine storm, cardiac injury, and coagulopathy compared to their male counterparts.

In the multivariable logistic regression model, we analyzed the factors with significant impact on mortality separately for males and females. Overall, IL-6 ≥ 14 pg/mL, leukocytosis, and lymphocytopenia were independent risk factors of death for both sexes. For male patients, advanced age (≥ 50 years), hypertension, the elevated PCT, CRP, and D-dimer were associated with increased odds of mortality. Meanwhile, IL-2R, IL-8, and cTnI were independent risks for higher mortality in females.

To further investigate the influence of risk factors, we plotted Kaplan-Meier curves to study the prognoses of patients based on the numbers of independent risk factors they had (Figure S4C,D). Males (females) who had 0-3 (0-2), 4-6 (3), and 7-8 (4-6) factors were regarded as low-risk, moderate-risk, and high-risk patients, respectively, and had diverse prognoses. 67.00% (75.93%) of the high-risk male (female) patients died while only 0.82% (0.77%) of the low-risk ones had fatal outcome. A summary of these findings is shown in Figure 1.

In conclusions, IL-6 ≥ 14 pg/mL, leukocytosis, and lymphocytopenia were found to be risk factors for mortality in both sexes. Advanced age, presence of hypertension, elevated D-dimer, CRP, and PCT were independent risk factors of death only in males, while elevated IL-2R, IL-8, and cTnI increased the risk of mortality in females. Increase in D-dimer and cTnI were observed in the second and third weeks of illness onset while multiple cytokines were found to be increased in the fifth and sixth weeks among those with high mortality. Cytokine storm was a major concern throughout the clinical course, especially in later stages of COVID-19 and among females. Whether early intervention with potential anti-inflammatory or anti-cytokine agents can improve the prognosis in COVID-19 remains to be seen. Risk stratification based on cytokine profile and other risk factors might be considerable in the management of COVID-19.

---

**FIGURE 1** Risk Management during the Clinical Course of COVID-19. Different strategies of risk management in different periods of COVID-19. Leukocytosis was defined as white blood cells count greater than $10 \times 10^9$/L. Lymphocytopenia was defined as lymphocyte count less than $0.8 \times 10^9$/L. Risk factors for male: age ≥ 50 years, with hypertension, D-dimer > 1 μg/mL, PCT ≥ 0.25 ng/mL, CRP > 10 mg/L, leukocytosis, lymphocytopenia, and IL-6 ≥ 14 pg/mL. Risk factors for female: IL-8 ≥ 62 pg/mL, IL-2R > 710 U/mL, cTnI > 15.6 pg/mL, leukocytosis, lymphocytopenia, and IL-6 ≥ 14 pg/mL. *Time from illness onset
ACKNOWLEDGMENTS
The study was supported by the National Science and Technology Major Sub-Project (2018ZX10301402-002), the Technical Innovation Special Project of Hubei Province (2018ACA138), the National Key Basic Research Program of China (2015CB553903), the National Natural Science Foundation of China (81572570, 81974405, 3182030, 31771458, 81772787, and 81873452), the Fundamental Research Funds for the Central Universities (2019kyfXMBZ024), and the Wuhan Municipal Health Commission (WX18Q16). We are grateful to all health-care workers and people nationwide and worldwide, who are involved in the fighting against COVID-19.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE
This study was approved by the Research Ethics Commission of Tongji Hospital of Huazhong University of Science and Technology (TJ-IRB20200406) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care. The trial has been registered in the Chinese Clinical Trial Registry (ChiCTR2000032161). The informed consents were waived by the Ethics Commission of Tongji Hospital of Huazhong University of Science and Technology.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTORS
QG had full access to all data in the study and take responsibility for the integrity of data and the accuracy of the data analysis. SZ, SW, YG, SX, RX, YW, and YY collected the clinical data. XJ, JC, YaY, CS, NJ, PC, JL, XZ, WG, XL, and GC double-checked and entered the data into database. DL, RL, XF, CL, and QG analyzed the clinical records. RL, RX, YW, XF, YY, HL, and AD drafted the manuscript. DL, QG, RL, RX, YW, XF, and YY analyzed and interpreted the data. CL, JS, and SK advised on the conception and design of the study. DL, CL, QG, and AD conceptualized and designed the study, supervised the project, and revised the manuscript. All authors vouch for the respective data and analysis, revised, approved the final version, and agreed to publish the manuscript. DL, RL, RX, YW, XF, and YY share first authorship, the order in which they are listed was determined by workload.

AVAILABILITY OF DATA AND MATERIAL
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

1 National Medical Center for Major Public Health Events, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
2 Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
3 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
4 The Elson S. Floyd College of Medicine, Washington State University, Pullman, Washington, USA
5 Medicine, University of British Columbia, Vancouver, Canada
6 Department of Medicine, University of Connecticut, Farmington, Connecticut, USA

Correspondence
Prof. Qinglei Gao, National Medical Center for Major Public Health Events, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430000, P. R. China.
Email: qingleigao@hotmail.com

Prof. Chunrui Li, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, 1095 Jie-Fang Avenue, Wuhan, Hubei, 430030, P. R. China.
Email: cunrui5650@hust.edu.cn

# These authors contributed equally

**KEYWORDS**
COVID-19, cytokine storm, mortality, risk factor

**ORCID**
Qinglei Gao https://orcid.org/0000-0002-9448-3423

**REFERENCES**
1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. *JAMA*. 2020;323:709-710.
2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-1034.
3. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. *Arthritis Rheumatology*. 2020.
4. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. *J Infect*. 2020;80(6):607-613.
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
7. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020;130(5):2620-2629.
8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section at the end of the article.